Trial of 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head and Neck Cancer
Status:
Completed
Trial end date:
2020-07-06
Target enrollment:
Participant gender:
Summary
This phase two trial will determine the tumor response rate at the primary site and at
involved regional nodes to two cycles of an IC regimen of weekly Abraxane and cetuximab given
in combination with cisplatin and 5-FU in patients with local regionally advanced HNSCC.